Viking Change To Account Receivables from 2010 to 2025

VKTX Stock  USD 33.69  0.26  0.78%   
Viking Therapeutics Change To Account Receivables yearly trend continues to be fairly stable with very little volatility. Change To Account Receivables is likely to outpace its year average in 2025. During the period from 2010 to 2025, Viking Therapeutics Change To Account Receivables regression line of annual values had r-squared of  0.67 and arithmetic mean of  107,672. View All Fundamentals
 
Change To Account Receivables  
First Reported
2010-12-31
Previous Quarter
369.1 K
Current Value
387.6 K
Quarterly Volatility
165.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 44.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.76. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Change To Account Receivables Growth Pattern

Below is the plot of the Change To Account Receivables of Viking Therapeutics over the last few years. It is Viking Therapeutics' Change To Account Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change To Account Receivables10 Years Trend
Slightly volatile
   Change To Account Receivables   
       Timeline  

Viking Change To Account Receivables Regression Statistics

Arithmetic Mean107,672
Geometric Mean0.00
Coefficient Of Variation153.57
Mean Deviation147,675
Median1,000.00
Standard Deviation165,357
Sample Variance27.3B
Range387.6K
R-Value0.82
Mean Square Error9.8B
R-Squared0.67
Significance0.0001
Slope28,366
Total Sum of Squares410.1B

Viking Change To Account Receivables History

2025387.6 K
2024369.1 K
2021321 K
2018 1000.0

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Change To Account Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change To Account Receivables369.1 K387.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.